# Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19

> **NCT04932915** · PHASE2 · TERMINATED · sponsor: **UNION therapeutics** · enrollment: 4 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Niclosamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04932915
- **Lead sponsor:** UNION therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-03
- **Primary completion:** 2022-01-10
- **Final completion:** 2022-01-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Failure of recruiting patients
- **Last updated:** 2022-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04932915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04932915, "Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04932915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*